Hanmi, “Failure experience of Olmutinib is the most valuable asset”

Hanmi Pharm held a press conference related to the recent olmutinib issue on the 2^nd at its head office located in Songpa-gu, Seoul, and answered to questions about Boehringer Ingelheim’s termination on the technology export agreement and the timing to announce the incident.

First, Vice President Jae-Sik Kim mentioned two cases of agreement that can play important roles in the management on t...